Axsome Therapeutics Inc (NASDAQ: AXSM)’s stock price has plunge by -0.01relation to previous closing price of 104.47. Nevertheless, the company has seen a 9.21% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-16 that NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached their fiduciary duties to shareholders.
Is It Worth Investing in Axsome Therapeutics Inc (NASDAQ: AXSM) Right Now?
Company’s 36-month beta value is 0.50.Analysts have differing opinions on the stock, with 13 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AXSM is 40.08M, and currently, short sellers hold a 12.84% ratio of that floaft. The average trading volume of AXSM on April 18, 2025 was 924.59K shares.
AXSM’s Market Performance
AXSM stock saw a decrease of 9.21% in the past week, with a monthly decline of -17.03% and a quarterly a decrease of 11.50%. The volatility ratio for the week is 3.68%, and the volatility levels for the last 30 days are 5.37% for Axsome Therapeutics Inc (AXSM). The simple moving average for the past 20 days is -4.53% for AXSM’s stock, with a 6.80% simple moving average for the past 200 days.
Analysts’ Opinion of AXSM
Many brokerage firms have already submitted their reports for AXSM stocks, with Jefferies repeating the rating for AXSM by listing it as a “Buy.” The predicted price for AXSM in the upcoming period, according to Jefferies is $200 based on the research report published on April 07, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see AXSM reach a price target of $176. The rating they have provided for AXSM stocks is “Buy” according to the report published on February 11th, 2025.
Mizuho gave a rating of “Outperform” to AXSM, setting the target price at $122 in the report published on December 31st of the previous year.
AXSM Trading at -12.18% from the 50-Day Moving Average
After a stumble in the market that brought AXSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.92% of loss for the given period.
Volatility was left at 5.37%, however, over the last 30 days, the volatility rate increased by 3.68%, as shares sank -17.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.37% lower at present.
During the last 5 trading sessions, AXSM rose by +9.21%, which changed the moving average for the period of 200-days by +28.92% in comparison to the 20-day moving average, which settled at $109.42. In addition, Axsome Therapeutics Inc saw 23.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AXSM starting from Pizzie Nick, who sale 12,000 shares at the price of $129.86 back on Feb 13 ’25. After this action, Pizzie Nick now owns 42,187 shares of Axsome Therapeutics Inc, valued at $1,558,320 using the latest closing price.
Pizzie Nick, the Chief Financial Officer of Axsome Therapeutics Inc, sale 3,000 shares at $131.07 during a trade that took place back on Feb 14 ’25, which means that Pizzie Nick is holding 42,187 shares at $393,210 based on the most recent closing price.
Stock Fundamentals for AXSM
Current profitability levels for the company are sitting at:
- -0.73 for the present operating margin
- 0.91 for the gross margin
The net margin for Axsome Therapeutics Inc stands at -0.74. The total capital return value is set at -0.83. Equity return is now at value -231.63, with -49.66 for asset returns.
Based on Axsome Therapeutics Inc (AXSM), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at 3.38. The interest coverage ratio of the stock is -42.92.
Currently, EBITDA for the company is -280.56 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 12.89. The receivables turnover for the company is 2.72for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.
Conclusion
In a nutshell, Axsome Therapeutics Inc (AXSM) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
